TABLE 1.
Demographics and clinical features
| Features | Cases, n = 284 | Controls, n = 284 | Cases vs. Controls, P Value | Odds Ratio (95% CI) for PSP Risk* |
|---|---|---|---|---|
| Age | 68.8 (7.01) | 69.0 (7.44) | 1.00 | – |
| Sex, female | 50.4 | 50.4 | 1.00 | – |
| Race | 1.00 | – | ||
| White or European American | 97.5 | 97.5 | ||
| Black or African American | 0.7 | 0.7 | ||
| Asian or Pacific Islander | 1.8 | 1.8 | ||
| Income | 0.067 | – | ||
| <$50,000/year | 36.4 | 27.1 | ||
| $50–80,000/year | 27.1 | 28.6 | ||
| >$80,000/year | 36.4 | 44.3 | ||
| Years of education | 14.7 (4.21) | 16.2 (4.07) | <0.001 | 0.89 (0.84–0.93) |
| Smoking, pack-years | 15.7 (25.1) | 10.5 (19.5) | 0.032 | 1.01 (1.01–1.02) |
| Years of drinking well water | 11.4 (17.0) | 7.10 (12.4) | 0.003 | 1.02 (1.01–1.04) |
| Age at symptom onset | 65.03 (7.01) | – | ||
| PSP symptom duration, years | 3.68 (1.76) | – | ||
| PSP Rating Scale | 36.3 (11.3) | – | ||
| UPDRS-Total | 51.7 (17.9) | – | ||
| UPDRS-Part III | 30.0 (12.3) | – | ||
| Dementia Rating Scale | 127 (10.8) | – | ||
| Neuropsychiatric Inventory | 10.1 (9.11) | – | ||
| Statin use | 20.8 | 30.6 | 0.011 | 0.61 (0.41–0.91) |
| Type 1 statins | 10.9 | 17.6 | 0.023 | 0.56 (0.34–0.92) |
| Type 2 statins | 11.6 | 14.8 | 0.27 | – |
| Age at first statin use | 59.2 (8.08) | 62.1 (8.08) | 0.19 | – |
| Duration of statin use, years | 7.48 (5.66) | 6.24 (5.69) | 0.97 | – |
| Reason for statin use | 0.80 | – | ||
| Hypercholesterolemia | 97.7 | 98.3 | ||
| Hypercholesterolemia & hypertension | 2.3 | 1.7 |
Variables are reported as mean (standard deviation) or percentage. Bold indicates statistical significance.
*
Only significant variables from the univariate regression models are shown.
CI, confidence interval; PSP, progressive supranuclear palsy; UPDRS, Unified Parkinson’s Disease Rating Scale.